COLUMBUS, Ohio The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.
The grant also funds Ohio State as a member of a nationwide Pharmacogenomics Research Network (PGRN), which connects 14 major centers across the United States with diverse specializations, working jointly to achieve this goal.
"It's estimated that 30 percent to 70 percent of people who take medication do not respond favorably and even have serious adverse reactions to it," says study leader Wolfgang Sadee, chair and professor of pharmacology, of pharmacy, of internal medicine, of psychiatry and of public health at The Ohio State University. Sadee also chairs Ohio State's Program in Pharmacogenomics.
Sadee notes that adverse drug reactions are a major cause of death and hospitalization in the United States. "We want to improve our ability to give the right drug to the right patient at the right time at the right dosage," adds Sadee.
"Because people are genetically different, they respond differently to medication," he says. "If we can identify these genetic differences, then we can prevent adverse drug reactions and predict which drugs will offer the best treatment for individual patients."
But critical genetic differences among individuals largely remain unknown, Sadee says. "Our project uses a novel approach to finding these critical genetic differences and testing them immediately in clinical trials that are under way here at Ohio State and across the world." The project will also support large-scale DNA sequencing using the latest technologies, enabling researchers to study the entire human genome.
The study led by Sadee targets genes that are important for major disease
|Contact: Darrell E. Ward|
Ohio State University Medical Center